DUTCH Test Medication-Driven Changes: What Your Results Actually Mean

Why Medications Change DUTCH Test Results

The DUTCH (Dried Urine Test for Comprehensive Hormones) test measures hormone metabolites excreted in urine over roughly 24 hours. That excretion pattern reflects three separate processes: how much hormone your glands produce, how fast your liver conjugates and hydroxylates each molecule, and how well your kidneys clear the final metabolites. Any drug that touches one of those three steps will shift the output.

The Test Is a Metabolite Snapshot, Not a Production Rate

A serum estradiol level reflects circulating hormone at one moment. The DUTCH test reflects cumulative metabolic processing. A woman on 0.05 mg transdermal estradiol patch may show serum E2 of 60 to 80 pg/mL, which looks physiologic. Her DUTCH total estrogen metabolites, however, may still read low or mid-range because transdermal delivery bypasses first-pass hepatic conversion, producing fewer urinary conjugates per picogram of circulating E2 [1].

Oral estrogen takes exactly the opposite path. It floods the liver with estrogen before reaching systemic circulation. The liver responds by generating large quantities of estrone sulfate and glucuronide conjugates, all of which appear in urine. The same circulating E2 level achieved orally versus transdermally can generate three to five times more urinary estrogen metabolite signal on the DUTCH test [2].

Why the 2-Hydroxyestrone to 16-Hydroxyestrone Ratio Matters

The 2-OH-E1 to 16-OH-E1 ratio (commonly called the 2:16 ratio) has been studied as a marker of estrogen detoxification favorability. Data from the Nurses' Health Study II (N=712) found that higher 2-OH-E1 was associated with modestly lower breast tissue density, a surrogate for breast cancer risk [3]. The optimal target ratio cited by most functional medicine laboratories is 2.0 or above.

Oral estrogen raises absolute 2-OH-E1 substantially, which can make the 2:16 ratio look favorable even when the 16-OH-E1 is also elevated. This is an artifact of dose and route, not improved detoxification. Clinicians who interpret a "good" 2:16 ratio on a patient taking oral estradiol 1 mg daily without accounting for route are reading an artifact.

How Exogenous Estrogen Alters DUTCH Values

Exogenous estrogen is the single largest source of medication-driven interpretation errors on DUTCH testing. The route of delivery determines the magnitude and pattern of the shift.

Oral Estrogens

Oral estradiol and oral conjugated equine estrogens both undergo extensive first-pass hepatic metabolism. The liver hydroxylates estradiol along the 2-, 4-, and 16-alpha pathways before conjugation. Because the liver sees a bolus of hormone with each dose, all three pathways get saturated, producing elevated 2-OH-E1, elevated 4-OH-E1, and elevated 16-OH-E1 simultaneously.

Reference ranges published by Precision Analytical (the laboratory that developed the DUTCH test) are calibrated to endogenous production in cycling women. On oral estradiol, total estrogen metabolites routinely land two to five times above the upper reference limit, even at modest doses like 1 mg estradiol daily. This does not mean the patient is at elevated risk. It means the test was designed for endogenous hormone, and oral delivery creates a non-physiologic hepatic load [4].

Practically: if a patient is on oral estrogen, the DUTCH metabolite absolute values cannot be compared to the standard reference range. The clinician should use the 2:16 ratio and the 4-OH-E1 proportion (ideally below 10% of total estrogen metabolites) as relative markers rather than the absolute values.

Transdermal Estrogen (Patches and Gels)

Transdermal delivery bypasses first-pass hepatic metabolism. Circulating estradiol enters tissues, exerts its effects, then gets cleared by the liver in the same way endogenous estradiol would. Urinary estrogen metabolites on transdermal estrogen tend to be lower relative to the circulating E2 level than on oral estrogen [2].

A woman achieving a serum E2 of 80 pg/mL via a 0.1 mg/day patch may show total DUTCH estrogen metabolites within or just above the normal reference range. This is expected and does not mean "poor absorption." The ratio pattern (2-OH-E1, 4-OH-E1, 16-OH-E1 relative proportions) remains interpretable on transdermal therapy, which is why most HRT-prescribing guidelines from the Menopause Society favor transdermal delivery for patients who need DUTCH monitoring [5].

Vaginal Estrogen

Low-dose vaginal estradiol (10 mcg Vagifem, 4 mcg Yuvafem, Estring ring) produces minimal systemic absorption. DUTCH urinary estrogen metabolites on vaginal-only therapy should be at or near the postmenopausal reference range. Values substantially above that range suggest either higher-than-expected systemic absorption or concurrent use of systemic estrogen the patient did not disclose.

Progesterone: Oral vs. Transdermal vs. Vaginal

Progesterone creates some of the most confusing DUTCH results in clinical practice.

Oral Micronized Progesterone (Prometrium)

Oral micronized progesterone (100 to 200 mg nightly) undergoes extensive first-pass hepatic conversion to pregnanediol glucuronide (PDG), allopregnanolone, and other metabolites. The DUTCH test measures pregnanediol (Pg) as the primary progesterone metabolite. On 200 mg oral Prometrium, DUTCH Pg values typically exceed the upper reference range by five to twenty times, and this reflects normal hepatic processing of a therapeutic dose, not an overdose [6].

Allopregnanolone, a neurosteroid metabolite of progesterone, also rises substantially on oral progesterone. The DUTCH test does not directly report allopregnanolone in all panel versions, but some advanced panels include it. The sedating effect many patients notice from oral Prometrium at bedtime is directly related to this allopregnanolone conversion.

Transdermal Progesterone Creams

Transdermal progesterone creams produce a different and clinically vexing pattern. Because progesterone is highly lipophilic, it deposits in adipose and skin tissue, creating a large reservoir that releases slowly. Serum progesterone levels on transdermal cream typically stay low (often below 1 ng/mL), suggesting inadequate absorption. DUTCH pregnanediol values, however, may rise ten to one hundred times above the upper reference range because the kidneys clear the accumulated tissue reservoir over time [7].

This divergence between low serum progesterone and extremely elevated DUTCH Pg is a known artifact of transdermal progesterone delivery. It does not mean the patient is receiving an overdose from an endocrine standpoint. The Endocrine Society's 2015 clinical practice guideline on postmenopausal hormone therapy notes that serum progesterone remains the more reliable marker of systemic progestogenic effect compared to urinary metabolites when transdermal cream is used [8].

Vaginal Progesterone

Vaginal progesterone (Crinone gel, Endometrin suppositories) achieves high local uterine concentrations through the utero-vaginal portal but produces modest systemic levels. DUTCH Pg on vaginal progesterone sits below what oral therapy produces but above baseline postmenopausal values. This route is interpretable on DUTCH with the caveat that the Pg value underestimates uterine tissue exposure.

Androgens: DHEA, Testosterone, and Their Metabolites

DHEA and DHEA-S Supplementation

DHEA supplements (25 to 50 mg daily) are among the most common over-the-counter hormone products. Within two to four weeks of starting DHEA, the DUTCH test shows elevated DHEA-S, elevated androsterone, elevated etiocholanolone, and, in women, elevated testosterone metabolites (5a-androstanediol, 5b-androstanediol). These downstream androgen metabolites may reach or exceed the upper reference limit even on a 25 mg dose that many patients consider "mild" [9].

In postmenopausal women, DHEA also converts to estrogens peripherally. The DUTCH test may show mildly elevated estrone and estradiol metabolites in a woman taking DHEA who believes she is taking "only an adrenal supplement," not hormone therapy. This conversion needs to be discussed during consent.

Topical and Injectable Testosterone

Testosterone therapy suppresses LH and FSH through negative feedback, which reduces endogenous testicular or ovarian testosterone production. On the DUTCH test, total androgen metabolites reflect both exogenous and residual endogenous production. The 5a-reductase metabolites (5a-androstanediol glucuronide, androsterone) rise in proportion to testosterone dose.

Women on testosterone cream (0.5 to 2 mg daily) typically show DUTCH androgen metabolites two to six times above the female reference range. This is expected at therapeutic doses and is not grounds for dose reduction unless symptoms of androgen excess appear. The ratio of 5a-reduced to 5b-reduced metabolites provides information about individual 5a-reductase activity, which varies by genetics and cannot be adjusted by dose alone [10].

Cortisol Pathway: Medications That Suppress or Mimic HPA Output

Exogenous Corticosteroids

Any exogenous glucocorticoid (prednisone, dexamethasone, hydrocortisone, inhaled fluticasone, topical triamcinolone) suppresses hypothalamic CRH and pituitary ACTH through negative feedback. The DUTCH test measures free cortisol and six cortisol metabolites (THF, 5a-THF, THE, cortisone, cortisol, and the cortisol:cortisone ratio).

On even low-dose prednisone (5 mg daily), DUTCH free cortisol may fall below 25 nM/mM (creatinine-adjusted), which sits below the lower reference limit. DHEA-S falls concurrently because adrenocortical zona reticularis output is suppressed alongside cortisol production. A patient on daily inhaled fluticasone for asthma may show a DUTCH cortisol profile that looks identical to mild adrenal insufficiency, even when adrenal function is entirely normal [11].

The DUTCH test is not a reliable diagnostic tool for adrenal insufficiency in patients on any corticosteroid product. Cosyntropin (ACTH stimulation) testing via serum remains the standard reference test per the Endocrine Society guideline on adrenal insufficiency [8].

Hydrocortisone Replacement Therapy

Patients already diagnosed with adrenal insufficiency and taking hydrocortisone 15 to 25 mg daily will show DUTCH free cortisol levels that reflect their dosing schedule rather than adrenal capacity. The diurnal cortisol awakening response curve on the DUTCH (which uses a waking + 30-minute sample) may appear blunted even on optimal replacement because the cortisol spike after waking is driven by endogenous ACTH, which is partially suppressed by even physiologic HC doses.

SSRIs, SNRIs, and Cortisol

Several studies show that SSRIs modestly lower salivary and urinary cortisol, likely through serotonin-mediated effects on CRH secretion. A meta-analysis published in Psychoneuroendocrinology (2017, N=1,243 patients across 14 trials) found that SSRI use was associated with a mean 10 to 15% reduction in morning cortisol, with the effect most pronounced for fluoxetine and paroxetine [12]. On the DUTCH test, this translates to free cortisol sitting in the lower-third of the reference range in otherwise healthy patients on SSRIs. This is probably a pharmacologic effect rather than true HPA suppression.

Melatonin Supplements and 6-OHMS

The DUTCH Plus panel includes 6-sulfatoxymelatonin (6-OHMS), the primary urinary melatonin metabolite, measured in the first morning urine sample. Reference ranges for 6-OHMS are calibrated to endogenous pineal production.

A 0.5 mg melatonin supplement taken before bed will roughly double 6-OHMS above the upper reference limit. A 5 mg dose, which is the most commonly sold US formulation, may raise 6-OHMS by 400 to 800%, producing a value that looks like a melatonin-secreting tumor on paper. The patient should discontinue melatonin supplements for at least five days before DUTCH collection for the 6-OHMS value to be interpretable.

The HealthRX Medication Disclosure Protocol for DUTCH Testing

Before ordering a DUTCH test, every HealthRX patient completes a structured medication and supplement disclosure that covers six categories: (1) systemic sex hormones (oral, patch, gel, cream, pellet, injection), (2) topical or vaginal hormones, (3) oral or injected corticosteroids, (4) inhaled or intranasal corticosteroids, (5) DHEA or pregnenolone supplements, and (6) melatonin. Results are then flagged in the report with a medication-context note so the reviewing clinician knows which values are medication-influenced versus physiologic.

This protocol reduces the rate of clinically meaningless dose changes prompted by medication-artifact results. Ordering a DUTCH test without this information is like reading a thyroid panel without knowing the patient is on levothyroxine.

Optimal and Normal DUTCH Test Ranges by Analyte

Reference ranges vary by laboratory, sex, menopausal status, and, critically, whether the patient is on exogenous hormones. The figures below reflect Precision Analytical's published reference intervals for premenopausal women (luteal phase) and postmenopausal women not on hormone therapy.

| Analyte | Premenopausal Luteal Reference | Postmenopausal (No HRT) Reference | |---|---|---| | Total Estrogen Metabolites | 150 to 750 ng/mg Cr | 20 to 100 ng/mg Cr | | 2-OH-E1 | 50 to 350 ng/mg Cr | 5 to 55 ng/mg Cr | | 4-OH-E1 | <15 ng/mg Cr | <8 ng/mg Cr | | 16-OH-E1 | 20 to 130 ng/mg Cr | 3 to 45 ng/mg Cr | | 2:16 ratio | 2.0 to 10.0 | 2.0 to 10.0 | | Pregnanediol (Pg) | 1,500 to 8,000 ng/mg Cr | <300 ng/mg Cr | | DHEA-S | 100 to 400 ng/mg Cr | 30 to 200 ng/mg Cr | | Free Cortisol (sum) | 50 to 200 nM/mM Cr | 50 to 200 nM/mM Cr | | Cortisol Awakening Response | Rise of 50%+ from waking to +30 min | Rise of 50%+ from waking to +30 min | | 6-OHMS (first morning urine) | 15 to 75 ng/mg Cr | 10 to 55 ng/mg Cr |

These are orientation targets, not treatment thresholds. Values falling outside these ranges because of medication should be noted in context before any clinical decision is made [4].

When to Retest and How to Time the Collection

Stopping Medications Before Testing

For interpretable results in specific analytes, the following washout guidance applies:

• Melatonin supplements: Stop 5 days before collection.
• Oral DHEA: Stop 7 to 14 days before collection if the goal is to assess endogenous adrenal output. If monitoring therapy, collect on therapy.
• Oral progesterone: If assessing endogenous progesterone status, test in the follicular phase and hold progesterone for 48 hours. If monitoring therapy, collect at steady state.
• Transdermal progesterone cream: The tissue reservoir can persist for weeks. A truly washout-based collection requires 4 to 6 weeks off cream, which is often not clinically feasible.
• Corticosteroids: Do not stop without physician direction. Document the dose and timing instead.

Cycle Day for Premenopausal Women

The DUTCH test should be collected on days 19 to 22 of a 28-day cycle (7 days after presumed ovulation) to capture luteal-phase progesterone and estrogen metabolites at their physiologic peak. Testing outside this window, particularly in the follicular phase, will show Pg values that look like anovulation even in cycling women.

A woman on a 28-day combined oral contraceptive pill will show near-zero Pg and extremely low endogenous LH-driven estrogen metabolites throughout her cycle. The DUTCH test provides essentially no endogenous hormonal information while a patient is on combined OCP. The test becomes interpretable 4 to 8 weeks after discontinuation [4].

Clinical Red Flags: Results That Are Almost Always Medication Artifacts

Four patterns on a DUTCH report should trigger immediate medication review before any clinical action:

1. Pregnanediol above 5,000 ng/mg Cr in a postmenopausal woman: Almost always transdermal progesterone cream or oral Prometrium, even if the patient did not disclose it.
2. Total estrogen metabolites above 1,000 ng/mg Cr in a postmenopausal woman: Almost always oral estrogen. Confirm route and dose.
3. Free cortisol below 30 nM/mM Cr with low DHEA-S in an otherwise well patient: High probability of exogenous corticosteroid use, including inhaled steroids.
4. 6-OHMS above 150 ng/mg Cr: Almost always melatonin supplements.

As the Endocrine Society's Position Statement on the Use of Biomarkers notes: "Urinary hormone metabolite testing provides clinically useful information only when collection conditions, medication context, and assay-specific reference ranges are interpreted together rather than in isolation" [8].